BRISTOL MYERS SQUIBB
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery
Phase 2
Completed
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 27
- Registration Number
- NCT00112580
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸NCI - Surgery Branch, Bethesda, Maryland, United States
Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome
Phase 4
Completed
- Conditions
- Metabolic SyndromeHypertension
- Interventions
- First Posted Date
- 2005-05-10
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 400
- Registration Number
- NCT00110422
- Locations
- 🇪🇸
Local Institution, Zaragoza, Spain
Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2005-04-01
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1440
- Registration Number
- NCT00106808
- Locations
- 🇺🇦
Local Institution, Simferopol, Ukraine
Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer
Phase 2
Terminated
- Conditions
- Prostate Cancer
- First Posted Date
- 2005-02-24
- Last Posted Date
- 2008-09-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 53
- Registration Number
- NCT00104130
- Locations
- 🇺🇸
Georgia Cancer Specialists, Tucker, Georgia, United States
🇺🇸Kaiser Permanente NW Oncology Clinic, Portland, Oregon, United States
🇺🇸Kaiser Permanente Medical Center, Vallejo, California, United States
Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2005-02-16
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00103831
- Locations
- 🇨🇦
Local Institution, Toronto, Ontario, Canada
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
Phase 2
Completed
- Conditions
- Chronic Myeloid LeukemiaPhiladelphia-Positive Myeloid Leukemia
- Interventions
- First Posted Date
- 2005-02-16
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 150
- Registration Number
- NCT00103844
- Locations
- 🇬🇧
Local Institution, Newcastle, Tyne and Wear, United Kingdom
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
Phase 1
Completed
- Conditions
- Leukemia, Myeloid, Chronic-phaseLeukemia, Lymphoblastic, Acute, Philadelphia-positive
- Interventions
- First Posted Date
- 2005-02-15
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00103701
- Locations
- 🇺🇸
Local Institution, Houston, Texas, United States
Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate
- First Posted Date
- 2005-01-14
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 124
- Registration Number
- NCT00101816
- Locations
- 🇬🇧
Local Institution, London, Greater London, United Kingdom
Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib
Phase 2
Completed
- Conditions
- Chronic Myeloid LeukemiaPhiladelphia-Positive Myeloid Leukemia
- Interventions
- First Posted Date
- 2005-01-13
- Last Posted Date
- 2012-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 387
- Registration Number
- NCT00101660
- Locations
- 🇬🇧
Local Institution, London, Greater London, United Kingdom
🇨🇭Local Instituion, Basel, Switzerland
Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia
- First Posted Date
- 2005-01-13
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 197
- Registration Number
- NCT00101647
- Locations
- 🇬🇧
Local Institution, London, Greater London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath